Modulating PD‐L1 expression is especially interesting in NSCLC tumors without targetable genetic alterations, because these have a more inflamed tumor microenvironment and respond better to immune checkpoint inhibitors than tumors with targetable genetic alterations, such as EGFR mutations 1, 2. The gene discussed is EGFR; the disease is neoplasm.